Development of a very rapid diagnostic test for malaria, based on break-through detection technology and new biomarkers of infection.

Informazioni relative al progetto

MalaDiag

ID dell’accordo di sovvenzione: 663824

DOI

10.3030/663824

Progetto chiuso

Data della firma CE 26 Febbraio 2015

Data di avvio 1 Dicembre 2014

Data di completamento 31 Maggio 2015

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

VAXIMAX
France

Periodic Reporting for period 1 - MalaDiag (Development of a very rapid diagnostic test for malaria, based on break-through detection technology and new biomarkers of infection.)

Periodo di rendicontazione: 2014-12-01 al 2015-05-31

Sintesi del contesto e degli obiettivi generali del progetto

This project was designed to test the technical and economic feasibility of a very rapid diagnostic test for malaria based on novel biomarkers developed by Vaximax and a radically new detection technology implemented by Metemis.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The study included a demonstration of prototype performance with regard to rapidity, sensitivity, specificity and robustness under expected field conditions. In addition, the device design and projected production costs were optimised to ensure competitiveness in low-income malaria endemic countries. Finally, an in-depth market study allowed us to identify the most attractive targets for commercialisation of the proposed MalaDiag device.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

See Final results published above

Vaximax